

Takemi Akahane

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5590166/publications.pdf>

Version: 2024-02-01

69
papers

1,229
citations

516561

16
h-index

434063

31
g-index

72
all docs

72
docs citations

72
times ranked

1297
citing authors

#	ARTICLE	IF	CITATIONS
1	Laser-cut-type versus braided-type covered self-expandable metallic stents for distal biliary obstruction caused by pancreatic carcinoma: a retrospective comparative cohort study. <i>Clinical Endoscopy</i> , 2022, 55, 434-442.	0.6	4
2	Ratio of von Willebrand factor antigen to ADAMTS13 activity is a useful biomarker for acute-on-chronic liver failure development and prognosis in patients with liver cirrhosis. <i>Hepatology Research</i> , 2022, 52, 390-400.	1.8	7
3	Autoimmune gastritis induces aberrant DNA methylation reflecting its carcinogenic potential. <i>Journal of Gastroenterology</i> , 2022, 57, 144-155.	2.3	9
4	Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on ongoing hepatic fibrosis. <i>Indian Journal of Gastroenterology</i> , 2022, 41, 169-180.	0.7	5
5	ADAMTS13, VWF, and Endotoxin Are Interrelated and Associated with the Severity of Liver Cirrhosis via Hypercoagulability. <i>Journal of Clinical Medicine</i> , 2022, 11, 1835.	1.0	8
6	Endotoxin Activity Reflects an Increase in Body Temperature in Cirrhotic Patients With Ascites Undergoing Cell-free and Concentrated Ascites Reinfusion Therapy. <i>In Vivo</i> , 2022, 36, 1477-1484.	0.6	0
7	Rifaximin and lubiprostone mitigate liver fibrosis development by repairing gut barrier function in diet-induced rat steatohepatitis. <i>Digestive and Liver Disease</i> , 2022, 54, 1392-1402.	0.4	7
8	Rifaximin enhances the L-carnitine-mediated preventive effects on skeletal muscle atrophy in cirrhotic rats by modulating the gut-liver-muscle axis. <i>International Journal of Molecular Medicine</i> , 2022, 50, .	1.8	5
9	Lenvatinib prevents liver fibrosis by inhibiting hepatic stellate cell activation and sinusoidal capillarization in experimental liver fibrosis. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 4001-4013.	1.6	11
10	Identification of the Response-Related Biomarker of Bimonthly Hepatic Arterial Infusion Chemotherapy. <i>Journal of Clinical Medicine</i> , 2021, 10, 629.	1.0	1
11	Current status of hepatitis test recognition and an attempt of an efficient screening test in an area with a low implementation rate of hepatitis screening. <i>Acta Hepatologica Japonica</i> , 2021, 62, 89-91.	0.0	1
12	Sulforaphane ameliorates ethanol plus carbon tetrachloride-induced liver fibrosis in mice through the Nrf2-mediated antioxidant response and acetaldehyde metabolism with inhibition of the LPS/TLR4 signaling pathway. <i>Journal of Nutritional Biochemistry</i> , 2021, 89, 108573.	1.9	58
13	The Angiotensin II Receptor Blocker Losartan Sensitizes Human Liver Cancer Cells to Lenvatinib-Mediated Cytostatic and Angiostatic Effects. <i>Cells</i> , 2021, 10, 575.	1.8	13
14	Role of serum albumin in hepatic encephalopathy. <i>Hepatology Research</i> , 2021, 51, 353-354.	1.8	0
15	Efficacy of Underwater Endoscopic Mucosal Resection for Superficial Non-Ampullary Duodenal Epithelial Tumor. <i>Clinical Endoscopy</i> , 2021, 54, 371-378.	0.6	16
16	Intestinal Permeability Is a Mechanical Rheostat in the Pathogenesis of Liver Cirrhosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6921.	1.8	16
17	Zinc Administration and Improved Serum Markers of Hepatic Fibrosis in Patients with Autoimmune Hepatitis. <i>Journal of Clinical Medicine</i> , 2021, 10, 2465.	1.0	6
18	Evidence-based clinical practice guidelines for liver cirrhosis 2020. <i>Hepatology Research</i> , 2021, 51, 725-749.	1.8	90

#	ARTICLE	IF	CITATIONS
19	Evidence-based clinical practice guidelines for Liver Cirrhosis 2020. <i>Journal of Gastroenterology</i> , 2021, 56, 593-619.	2.3	158
20	Clinical Significance of Gamma-Glutamyltranspeptidase Combined with Carbohydrate-Deficient Transferrin for the Assessment of Excessive Alcohol Consumption in Patients with Alcoholic Cirrhosis. <i>Medicines (Basel, Switzerland)</i> , 2021, 8, 39.	0.7	4
21	The association between sarcopenia and endotoxin in patients with alcoholic cirrhosis. <i>Medicine (United States)</i> , 2021, 100, e27212.	0.4	10
22	Comparison of the efficacy and safety between palliative biliary stent placement and duct clearance among elderly patients with choledocholithiasis: a propensity score-matched analysis. <i>BMC Gastroenterology</i> , 2021, 21, 369.	0.8	2
23	Angiotensin Receptor Blockers Potentiate the Protective Effect of Branched-Chain Amino Acids on Skeletal Muscle Atrophy in Cirrhotic Rats. <i>Molecular Nutrition and Food Research</i> , 2021, 65, e2100526.	1.5	5
24	The Combination of Albumin-Bilirubin Score and Prothrombin Time Is a Useful Tool for Predicting Liver Dysfunction after Transcatheter Arterial Chemoembolization in Child-Pugh Class A Patients with Hepatocellular Carcinoma within Up-to-Seven Criteria. <i>Journal of Clinical Medicine</i> , 2021, 10, 4838.	1.0	4
25	Association between Equol Production Status and Nonalcoholic Steatohepatitis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11904.	1.8	6
26	Ascites symptom inventory-7 is a valuable tool for evaluating the effectiveness of tolvaptan in patients with cirrhotic ascites. <i>Experimental and Therapeutic Medicine</i> , 2021, 21, 30.	0.8	0
27	Factors associated with portopulmonary hypertension. <i>Hepatology Research</i> , 2021, 51, 1179-1180.	1.8	0
28	Dual therapy with zinc acetate and rifaximin prevents from ethanol-induced liver fibrosis by maintaining intestinal barrier integrity. <i>World Journal of Gastroenterology</i> , 2021, 27, 8323-8342.	1.4	10
29	Effect of furosemide on muscle cramps in patients with liver cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 76-81.	1.4	6
30	Thyroid-stimulating hormone is an independent risk factor of non-alcoholic fatty liver disease. <i>JGH Open</i> , 2020, 4, 400-404.	0.7	30
31	Effectiveness of Lusutrombopag in Patients with Mild to Moderate Thrombocytopenia. <i>Digestive Diseases</i> , 2020, 38, 329-334.	0.8	5
32	Atorvastatin Augments Gemcitabine-Mediated Anti-Cancer Effects by Inhibiting Yes-Associated Protein in Human Cholangiocarcinoma Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7588.	1.8	10
33	Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5589.	1.8	21
34	Accuracy of Fibrosis-4 Index in Identification of Patients with Cirrhosis Who Could Potentially Avoid Variceal Screening Endoscopy. <i>Journal of Clinical Medicine</i> , 2020, 9, 3510.	1.0	7
35	Increased Endotoxin Activity Is Associated with the Risk of Developing Acute-on-Chronic Liver Failure. <i>Journal of Clinical Medicine</i> , 2020, 9, 1467.	1.0	8
36	Association between Non-Alcoholic Fatty Liver Disease and Chronic Kidney Disease: A Cross-Sectional Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 1635.	1.0	11

#	ARTICLE	IF	CITATIONS
37	Hydralazine Sensitizes to the Antifibrotic Effect of 5-Aza-2â€²-deoxycytidine in Hepatic Stellate Cells. <i>Biology</i> , 2020, 9, 117.	1.3	2
38	Effect of three or more treatments with lusutrombopag in patients with cirrhotic thrombocytopenia: A retrospective singleâ€center study. <i>Hepatology Research</i> , 2020, 50, 1101-1105.	1.8	5
39	Bile Acid Sequestrant, Sevelamer Ameliorates Hepatic Fibrosis with Reduced Overload of Endogenous Lipopolysaccharide in Experimental Nonalcoholic Steatohepatitis. <i>Microorganisms</i> , 2020, 8, 925.	1.6	18
40	Gut dysbiosis associated with clinical prognosis of patients with primary biliary cholangitis. <i>Hepatology Research</i> , 2020, 50, 840-852.	1.8	46
41	Chronic Alcohol Consumption is Inversely Associated with Insulin Resistance and Fatty Liver in Japanese Males. <i>Nutrients</i> , 2020, 12, 1036.	1.7	9
42	Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients. <i>Antibiotics</i> , 2020, 9, 145.	1.5	33
43	Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2164.	1.8	12
44	Association between ADAMTS13 activityâ€™VWF antigen imbalance and the therapeutic effect of HAIC in patients with hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2020, 26, 7232-7241.	1.4	11
45	Effect of Lâ€™carnitine on healthâ€™related quality of life in patients with liver cirrhosis. <i>Biomedical Reports</i> , 2020, 13, 1-1.	0.9	7
46	Comparison of serum fibrosis biomarkers for diagnosing significant liver fibrosis in patients with chronic hepatitis B. <i>Experimental and Therapeutic Medicine</i> , 2020, 20, 985-995.	0.8	12
47	Ascites symptom inventory-7 is a valuable tool for evaluating the effectiveness of tolvaptan in patients with cirrhotic ascites. <i>Experimental and Therapeutic Medicine</i> , 2020, 21, 1-1.	0.8	2
48	VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma. <i>BMC Gastroenterology</i> , 2019, 19, 167.	0.8	20
49	Late-Evening Snack with Branched-Chain Amino Acid-Enriched Nutrients Does Not Always Inhibit Overt Diabetes in Patients with Cirrhosis: A Pilot Study. <i>Nutrients</i> , 2019, 11, 2140.	1.7	4
50	TGR5 Activation Modulates an Inhibitory Effect on Liver Fibrosis Development Mediated by Anagliptin in Diabetic Rats. <i>Cells</i> , 2019, 8, 1153.	1.8	16
51	Combined effect of a farnesoid X receptor agonist and dipeptidyl peptidaseâ€™4 inhibitor on hepatic fibrosis. <i>Hepatology Research</i> , 2019, 49, 1147-1161.	1.8	9
52	Identification of clinical risk factors for histological progression of primary biliary cholangitis. <i>Hepatology Research</i> , 2019, 49, 1015-1025.	1.8	9
53	Proton pump inhibitor therapy does not increase serum endotoxin activity in patients with cirrhosis. <i>Hepatology Research</i> , 2019, 49, 232-238.	1.8	9
54	Combining probiotics and an angiotensinâ€™ type 1 receptor blocker has beneficial effects on hepatic fibrogenesis in a rat model of nonâ€™alcoholic steatohepatitis. <i>Hepatology Research</i> , 2019, 49, 284-295.	1.8	25

#	ARTICLE	IF	CITATIONS
55	Bi-monthly hepatic arterial infusion chemotherapy as a novel strategy for advanced hepatocellular carcinoma in decompensated cirrhotic patients. <i>Clinical and Molecular Hepatology</i> , 2019, 25, 381-389.	4.5	11
56	Acylcarnitine: Useful biomarker for early diagnosis of hepatocellular carcinoma in non-steatohepatitis patients. <i>World Journal of Gastrointestinal Oncology</i> , 2019, 11, 887-897.	0.8	5
57	ADAMTS13 and von Willebrand factor are useful biomarkers for sorafenib treatment efficiency in patients with hepatocellular carcinoma. <i>World Journal of Gastrointestinal Oncology</i> , 2019, 11, 424-435.	0.8	8
58	Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection. <i>Clinical and Molecular Hepatology</i> , 2019, 25, 65-73.	4.5	4
59	Efficacy of bi-monthly hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 741-749.	0.6	12
60	von Willebrand factor is a useful biomarker for liver fibrosis and prediction of hepatocellular carcinoma development in patients with hepatitis B and C. <i>United European Gastroenterology Journal</i> , 2018, 6, 1401-1409.	1.6	27
61	Efficacy and tolerability of interferon-free regimen for patients with genotype 1 HCV infection. <i>Experimental and Therapeutic Medicine</i> , 2018, 16, 2743-2750.	0.8	4
62	Treatment of long-segment Barrett's adenocarcinoma by complete circular endoscopic submucosal dissection: a case report. <i>BMC Gastroenterology</i> , 2018, 18, 16.	0.8	6
63	Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on hepatic fibrosis. <i>Hepatology Communications</i> , 2017, 1, 928-945.	2.0	11
64	Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity. <i>World Journal of Gastroenterology</i> , 2017, 23, 8355-8366.	1.4	85
65	Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat. <i>BMC Research Notes</i> , 2009, 2, 70.	0.6	48
66	Impact of insulin resistance on the progression of chronic liver diseases. <i>International Journal of Molecular Medicine</i> , 2008, 22, 801-8.	1.8	26
67	Angiotensin-II and vascular endothelial growth factor interaction plays an important role in rat liver fibrosis development. <i>Hepatology Research</i> , 2006, 36, 124-129.	1.8	30
68	Leptin-mediated neovascularization is a prerequisite for progression of nonalcoholic steatohepatitis in rats. <i>Hepatology</i> , 2006, 44, 983-991.	3.6	142
69	Atrial fibrillation induced by simvastatin treatment in a 61-year-old man. <i>Heart and Vessels</i> , 2003, 18, 157-159.	0.5	7